Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Biogen’s R&D chief Ehlers heads for the exit

There’s still plenty in the neuroscience pipeline however, including tofersen for amyotrophic lateral sclerosis (ALS) which stems from an alliance with antisense specialist Ionis and is due for a phase

Latest news

Amgen reveals more data on KRAS drug

race, which include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring, Merck/Moderna and AstraZeneca/Ionis.
GSK to develop Ionis hepatitis B drugs

GlaxoSmithKline has exercised its option to license Ionis' antisense medicines for chronic hepatitis B virus (CHB) infection, boosting its presence in virology. ... polyneuropathy in adults with hereditary transthyretin amyloidosis which Ionis launched
Alnylam gains key NICE approval for Onpattro

Marketed by Ionis subsidiary Akcea Therapeutics, Tegsedi stole a march over Onpattro when it gained NICE approval in April, but now Alnylam has a matching recommendation from England’s cost watchdog.
Twentyeight-Seven raises another $15m for non-coding RNA drugs

the likes of Ionis/Akcea and Alnylam.
Akcea gets first OK for Waylivra in rare triglyceride disorder

The EU is the first market for the new drug. It’s a big win for Akcea, a subsidiary of Ionis, as the US FDA turned down its marketing application for

More from news
Approximately 15 fully matching, plus 29 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration